Efficacy and Safety Evaluation of a Novel Botulinum Toxin Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines

Dermatologic Surgery (Impact Factor: 1.56). 11/2010; 36(s4):2111 - 2118. DOI: 10.1111/j.1524-4725.2010.01711.x
Source: PubMed

ABSTRACT BACKGROUND Botulinum toxin type A (BoNTA) is commonly injected to treat facial wrinkles. Complications include pain, erythema, bruising, and potential infection. RT001 Botulinum Toxin Type A Topical Gel (RT001) is under development for the treatment of lateral canthal lines (LCLs).OBJECTIVE To assess the efficacy and safety of RT001 for the treatment of LCLs using a randomized, double-blind, repeat-dose, placebo-controlled study design.METHODS & MATERIALS Healthy adult subjects were randomized to receive RT001 (N=19) or placebo (N=17) applied to their lateral canthal areas (LCAs). To evaluate safety of repeat exposure, treatment was administered at baseline and week 4. The primary efficacy measure was improvement in baseline LCL severity using the Investigator's Global Assessment of Lateral Canthal Line at Rest (IGA-LCL) Severity Scale.RESULTS At 8 weeks, 19 (50%) LCAs treated with RT001 showed a 2-point or greater improvement in baseline IGA-LCL severity, versus none (0%) of the placebo-treated subjects (p<.001); 36 (94.7%) LCAs treated with RT001 showed a 1-point or more improvement in baseline IGA-LCL severity, versus five (14.7%) placebo-treated LCAs (p<.001). There were no treatment-related adverse events.CONCLUSION RT001 was well tolerated and demonstrated an improvement in LCLs.This study was sponsored by Revance Therapeutics, Inc., Newark, CA.

Download full-text


Available from: Jacob M Waugh, Apr 02, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rhinitis affects a significant proportion of adults and children with typically seasonal or chronic symptoms. Botulinum neurotoxin type A (BoNTA) is a well-known cholinergic antagonist widely used in a number of approved neurological and esthetic indications. This study was designed to assess the therapeutic effect of RT001, a novel topical gel formulation of BoNTA, in the treatment of allergic rhinitis using a rat model and to compare its safety profile with that of an aqueous formulation of BoNTA complex. A rat model of allergic rhinitis was used involving induction of classic rhinitis signs (sneezing and nasal itch) in addition to nasal inflammatory pathology to assess the degree of therapeutic effect of RT001. Comparative safety of RT001 and BoNTA complex was assessed in guinea pigs based on lethality and body weight gain. Clinical signs of rhinitis were significantly (p < 0.01) relieved after a single intranasal administration of RT001 and resolved to normal baseline levels within 5 days after treatment. Mucosal inflammation characterized by edema, congestion, and vascular dilatation along with increased expression of vasoactive intestinal peptide was noted in control animals after allergy induction, whereas RT001 treatment resolved inflammation to essentially normal baseline levels. Safety studies in guinea pigs via intranasal dosing revealed ∼31-fold greater safety factor for RT001 when compared with BoNTA complex. These results suggest that topical intranasal application of RT001 is effective in relief of clinical signs and inflammatory pathology associated with allergic rhinitis in a rodent model and may provide a safe treatment for rhinitis.
    American Journal of Rhinology and Allergy 11/2012; 26(6):450-4. DOI:10.2500/ajra.2012.26.3785 · 2.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is a concise review of the uses of botulinum toxins (BTXs) in dermatology and cosmetic procedures. It is a clinical rather than a basic science, pharmacological review. BTX had been initially used for selectively reducing and balancing periorbital muscle activity; thereby, reducing childhood strabismus and blepharospasm. This clinical research was initiated by Dr. Alan Scott over 40 years ago. BTX type A (BTX-A) was serendipitously observed to reduce forehead frown lines in patients being treated for blepharospasm. Extensive clinical research and development resulted in widespread aesthetic uses for BTX-A by reduction of selected hyperfunctional facial muscles. BTXs are also used for reduced localized hyperhidrosis. A topical BTX-A is being developed as a potential alternative to injected BTX.
    12/2012; 2(1):14. DOI:10.1007/s13555-012-0014-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Eine Hyperhidrose des Amputationsstumpfs gehört zu den häufigsten Ursachen einer eingeschränkten Prothesennutzung und Lebensqualität. Sie betrifft etwa 30–50% der Amputierten, 25% leiden zudem unter Hautirritationen. Dies begünstigt möglicherweise Stumpf- und Phantomschmerzen. Diese treten bei geringer Prothesennutzung vermehrt auf. Der Verlauf beider Schmerzarten nach Hyperhidrosisbehandlung von 9 Beinamputierten durch i.c.-Gabe von Botulinumtoxin Typ B (BTX-B) wird in dieser Arbeit beschrieben. Material und Methoden 9 Beinamputierten mit Stumpfschwitzen wurden zur Behandlung 1750 Einheiten BTX-B injiziert (je 20 i.c.-Injektionen). Vorher sowie nach 4 Wochen und 3 Monaten wurden die Durchschnittswerte der Schmerzstärke [numerische Rating-Skala (NRS): 0–10] der vergangenen Woche für Stumpf- und Phantomschmerzen sowie die Werte für die Beeinträchtigungen bezüglich Stumpfschwitzen, Prothesennutzung und Lebensqualität erfragt. Ergebnisse Stumpfschmerzen (n=9) verbesserten sich in dieser sehr kleinen Beobachtungsgruppe nach 3 Monaten hochsignifikant [NRS initial: 5 (4–8); NRS nach 4 Wochen: 4 (3–5), p=0,109; NRS nach 3 Monaten: 3 (2–4), p=0,008], Phantomschmerzen (n=8) tendenziell ebenfalls nach 3 Monaten [NRS initial: 5 (2–8); NRS nach 3 Monaten: 3 (2–5), p=0,109]. Das Stumpfschwitzen vor BTX-B-Gabe wurde durchschnittlich mit einem NRS-Wert von 7 (Interquartilabstand: 6–10) angegeben und verbesserte sich signifikant nach 4 Wochen (NRS: 3 (2–4), p=0,027) und nach 3 Monaten (NRS: 3 (1–4), p=0,020), entsprechend verbesserten sich auch die Beeinträchtigung der Prothesennutzungsdauer (NRS initial: 8; NRS nach 4 Wochen: 2, p=0,023; NRS nach 3 Monaten: 3, p=0,023) und der Lebensqualität (p=0,016 bzw. p=0,023). Schlussfolgerungen Die niedrig dosierte i.c.-Gabe von BTX-B verbesserte Stumpfschmerzen in einer Untersuchung an 9 Beinamputierten nach 3 Monaten, auch bestehende Phantomschmerzen verbesserten sich tendenziell. Es wird vermutet, dass das reduzierte Stumpfschwitzen und die dadurch verlängerte Prothesennutzungsdauer die Ursache hierfür sind. Die Ergebnisse und Schlussfolgerungen über mögliche Zusammenhänge sollten in größeren Untersuchungen geprüft werden.
    Der Schmerz 04/2012; 26(2-2):176-184. DOI:10.1007/s00482-011-1140-2 · 1.50 Impact Factor